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Currently satisfactory clinical results are observed withthe extracardiac Fontan operation (ECFO); however,some issues associated with graft materials must beaddressed, such as infection, thrombogenicity, and the
lack of growth potential.1 We report here the case of a patient with
occlusion of a graft implanted at initial operation and successfully
underwent reoperative ECFO with a tissue-engineered graft.
Clinical Summary
A 12-year-old boy had the diagnoses of polysplenia, complete
atrioventricular septal defect, small left ventricle, common atrium,
bilateral superior vena cava, and hemiazygous connection. A mod-
ified Blalock-Taussig shunt and ECFO with a Hemashield graft
(Boston Scientific Corporation, Meadox Division, Boston, Mass)
were performed at the ages of 9 and 11 years, respectively. The
patient had general fatigue 7 months after ECFO. Catheterization
demonstrated occlusion of the extracardiac graft. The clinical
application of tissue engineering in this patient was approved by
the ethical committee at Tokyo Women’s Medical University, and
the patient’s parents were thoroughly informed and consented to
the procedure. Graft replacement with a tissue-engineered graft
was planned, and graft preparation was conducted.
An approximately 2-cm segment of peripheral vein was har-
vested, and cells from its walls were isolated. The cells were
cultured and expanded as previously described elsewhere.2 The
tubular scaffold for these cells was composed of a polycaprolac-
tone–polylactic acid copolymer (weight ratio 1:1) reinforced with
woven polyglycolic acid. The synthetic biodegradable polymer
conduit (20 mm in diameter and 1 mm in thickness) was designed
so that it would be degraded within 8 weeks. Ten days after
seeding, the replacement of the occluded conduit was performed
by transplantation of the tissue-engineered graft.
Intraoperative findings showed that the conduit was completely
collapsed and flattened, with white thrombus contained within.
Pump perfusion was established with ascending aortic and single
left superior vena caval cannulation. Finally, the conduit was
completely removed, but hepatic veins were completely occluded
and no lumen was found. Therefore the diaphragm was cut open in
the midline, and the incision was extended to the hepatic veins.
Tissue-engineered conduit 20 mm in diameter was anastomosed
with 4-0 Prolene suture (Ethicon, Inc, Somerville, NJ) to the
hepatic venous stump (Figure 1). The main pulmonary artery end
was opened along its previous anastomotic orifice into the right
pulmonary artery, and the other end of the conduit was anasto-
mosed with the orifice. Intraoperative transesophageal echocardi-
ography showed patent graft flow, and the patient was discharged
from the hospital in good clinical condition. Postoperative com-
puted tomography done 4 months after the operation revealed a
patent graft (Figure 2).
Discussion
Significant developments have been made in the field of tissue
engineering, and many clinical applications have been found in
recent years. Previously we have reported the successful results of
surgical implantation of tissue-engineered pulmonary valve leaflet,
pulmonary artery, and inferior vena cava in large animal models.2,3
On the basis of such reliable evidence, the first clinical application
was successfully done in May 2000 with a tissue-engineered patch
for pulmonary arterial angioplasty.4 The creation of tissue-engi-
neered structures from autologous cells offers many potential
advantages: elimination of the problems of rejection and donor
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Figure 1. Intraoperative photograph. Tissue-engineered conduit 20
mm in diameter was anastomosed between hepatic venous stump
and previous anastomotic orifice of main pulmonary artery with
4-0 Prolene suture (Ethicon, Inc, Somerville, NJ).
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scarcity, greater durability and longevity because of the tissue’s
natural mechanism for repair and remodeling, lack of foreign body
response or need for long-term anticoagulation, and potential for
growth, which last is important in the pediatric age group. The
major drawbacks and main points of criticism of the ECFO are
lack of growth potential and thrombogenicity of the conduit.
Hemiazygous continuation of the inferior vena cava in which
conduit carries only hepatic venous flow may especially have a
higher risk of thrombosis.5 In response to concerns related to the
Dacron polyester fabric conduit in the venous system that we used
in the initial operation, we believed that there could be less chance
of obstruction because the conduit interposed between the inferior
vena cava and the pulmonary artery relies on a better hydrody-
namic pattern with uniform caliber and less turbulence, regardless
of graft material used.6
We believe that tissue-engineered prostheses could be useful in
such complicated cases, and their indications would be increased
for other kinds of cases. There remain limitations of this method in
the clinical setting. First, a tissue-engineered graft cannot be pre-
pared for an emergency operation because of the prolonged in vitro
times necessary for development of tissues. Second, sufficient cell
proliferation cannot be accomplished in all patients, and in such
cases we have to prepare cells from other part of the body. Third,
tissue-engineered grafts cannot be used in systemic circulation in
which proper biodegradable scaffold is now developing. Finally,
small diameter vascular grafts may occlude during early follow-up.
To find solutions for these issues, we are continuing experimental
studies.
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Figure 2. Postoperative computed tomographic scan. Graft is
patent, and no thrombus formation is seen. Polymer scaffold has
completely disappeared.
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